MMP14 | M10: Matrix metallopeptidase | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲


Target id: 1638

Nomenclature: MMP14

Family: M10: Matrix metallopeptidase

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     MMP14 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 582 14q11-q12 MMP14 matrix metallopeptidase 14
Mouse - 582 14 C2 Mmp14 matrix metallopeptidase 14 (membrane-inserted)
Rat - 582 15p13 Mmp14 matrix metallopeptidase 14
Previous and Unofficial Names
MMP- X1 | membrane type 1 metalloprotease | membrane-type matrix metalloproteinase 1 | MT1MMP | MTMMP1 | Membrane type 1-MMP | matrix metallopeptidase 14 (membrane-inserted)
Database Links
Specialist databases
MEROPS M10.014 (Hs)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
RefSeq Nucleotide
RefSeq Protein
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
compound 29e [PMID: 23631440] Hs Inhibition 8.4 pKi 2
pKi 8.4 (Ki 4x10-9 M) [2]
ilomastat Hs Inhibition 7.6 pIC50 4
pIC50 7.6 (IC50 2.3x10-8 M) [4]
CGS-27023A Hs Inhibition 7.6 pIC50 5
pIC50 7.6 (IC50 2.3x10-8 M) [5]
Clinically-Relevant Mutations and Pathophysiology
Disease:  Multicentric osteolysis, nodulosis, and arthropathy
Synonyms: Nodulosis-arthropathy-osteolysis syndrome [Orphanet: ORPHA85196]
OMIM: 259600
Orphanet: ORPHA85196
Disease:  Winchester syndrome
OMIM: 277950
Orphanet: ORPHA3460


Show »

1. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A et al.. (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res., 69 (4): 1517-26. [PMID:19208838]

2. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J. Med. Chem., 56 (11): 4357-73. [PMID:23631440]

3. Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A, Itoh Y. (2016) Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade. Arthritis Rheumatol, 68 (2): 521-31. [PMID:26315469]

4. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg. Med. Chem. Lett., 14 (1): 47-50. [PMID:14684295]

5. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]

6. Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, Gay S. (2000) Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum., 43 (6): 1226-32. [PMID:10857781]

7. Sabeh F, Fox D, Weiss SJ. (2010) Membrane-type I matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function. J. Immunol., 184 (11): 6396-406. [PMID:20483788]

How to cite this page

M10: Matrix metallopeptidase: MMP14. Last modified on 06/04/2018. Accessed on 18/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY,